Mucopolysaccharidosis type 4A

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:309297OMIM:253000E76.2
Who is this for?
Show terms as
1FDA treatments1Active trials6Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Mucopolysaccharidosis type 4A (MPS 4A), also known as Morquio A syndrome or Morquio disease type A, is a rare inherited metabolic disorder. It belongs to a group of conditions called lysosomal storage diseases. In this condition, the body cannot produce enough of an enzyme called N-acetylgalactosamine-6-sulfatase (GALNS). This enzyme is needed to break down certain complex sugars called glycosaminoglycans (GAGs), specifically keratan sulfate and chondroitin-6-sulfate. When these sugars build up in the body's cells, they cause progressive damage, especially to bones, cartilage, and connective tissues. The hallmark features of Morquio A syndrome include short stature, skeletal abnormalities, and joint problems. Children often appear normal at birth but begin showing signs in early childhood. Common problems include a short trunk, knock-knees, a prominent chest (pectus carinatum), spinal abnormalities, and loose joints. The neck can be particularly affected, with instability of the upper spine that can be dangerous. Unlike some other types of MPS, intelligence is usually normal in Morquio A syndrome. However, the disease can also affect the heart, eyes, ears, and breathing. Treatment options have expanded in recent years. An enzyme replacement therapy called elosulfase alfa (Vimizim) was approved by the FDA in 2014 and helps slow the progression of the disease. Supportive care including orthopedic surgeries, physical therapy, and monitoring of the heart and airways remain essential parts of management. Hematopoietic stem cell transplant is being explored but is not yet standard treatment for this type of MPS.

Also known as:

Key symptoms:

Short stature with a short trunkKnock-knees (legs bowing inward)Prominent or pigeon-shaped chestSpinal curvature or abnormalitiesLoose and overly flexible jointsInstability of the upper neck bonesWaddling walk or difficulty walkingClouding of the cornea in the eyesHearing lossHeart valve problemsBreathing difficultiesFrequent ear infectionsDental abnormalities including thin enamel and widely spaced teethEnlarged liverReduced endurance and fatigue

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

1 event
Sep 2023Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI

University of California, San Francisco — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

VIMIZIM

ELOSULFASE ALFA· BioMarin Pharmaceutical Inc.■ Boxed Warning

VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)

Clinical Trials

1 recruitingView all trials with filters →

Specialists

6 foundView all specialists →
DL
Debra Lounsbury
Specialist
PI on 5 active trials1 Mucopolysaccharidosis type 4A publication
TM
Tippi MacKenzie, MD
San Francisco, California
Specialist

Rare Disease Specialist

PI on 2 active trials
CM
Celeste Decker, MD
CONCORD, NH
Specialist
PI on 5 active trials
SP
Shunji Tomatsu, MD PhD
Specialist
PI on 1 active trial
EP
Ellen B Fung, PhD
OAKLAND, CA
Specialist
PI on 1 active trial
RM
Richard Curtis Rogers, MD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
VIMIZIM(ELOSULFASE ALFA)BioMarin Pharmaceutical Inc.

Travel Grants

No travel grants are currently matched to Mucopolysaccharidosis type 4A.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Mucopolysaccharidosis type 4AForum →

No community posts yet. Be the first to share your experience with Mucopolysaccharidosis type 4A.

Start the conversation →

Latest news about Mucopolysaccharidosis type 4A

No recent news articles for Mucopolysaccharidosis type 4A.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my child's form of Morquio A, and what can we expect over time?,Is the cervical spine (neck) stable, and when should we consider spinal surgery?,Should we start enzyme replacement therapy (Vimizim), and what are the benefits and risks?,How often do we need imaging of the spine, heart, and other organs?,What activities should we avoid to protect the neck and spine?,Are there any clinical trials for new treatments that we should consider?,What precautions are needed if my child ever needs surgery or anesthesia?

Common questions about Mucopolysaccharidosis type 4A

What is Mucopolysaccharidosis type 4A?

Mucopolysaccharidosis type 4A (MPS 4A), also known as Morquio A syndrome or Morquio disease type A, is a rare inherited metabolic disorder. It belongs to a group of conditions called lysosomal storage diseases. In this condition, the body cannot produce enough of an enzyme called N-acetylgalactosamine-6-sulfatase (GALNS). This enzyme is needed to break down certain complex sugars called glycosaminoglycans (GAGs), specifically keratan sulfate and chondroitin-6-sulfate. When these sugars build up in the body's cells, they cause progressive damage, especially to bones, cartilage, and connective t

How is Mucopolysaccharidosis type 4A inherited?

Mucopolysaccharidosis type 4A follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Mucopolysaccharidosis type 4A typically begin?

Typical onset of Mucopolysaccharidosis type 4A is childhood. Age of onset can vary across affected individuals.

Are there clinical trials for Mucopolysaccharidosis type 4A?

Yes — 1 recruiting clinical trial is currently listed for Mucopolysaccharidosis type 4A on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Mucopolysaccharidosis type 4A?

6 specialists and care centers treating Mucopolysaccharidosis type 4A are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Mucopolysaccharidosis type 4A?

1 patient support program are currently tracked on UniteRare for Mucopolysaccharidosis type 4A. See the treatments and support programs sections for copay assistance, eligibility, and contact details.